
NCCN Low/Very Low Risk
Example Test Report



ARTERA

Name: **John Doe**
Date of Birth: **08/08/1954**

ArteraAI Prostate Test Report

PATIENT DETAILS

PATIENT
Name: **John Doe**
Date of Birth: **08/08/1954**
Condition: **Prostate Cancer**

PHYSICIAN
Name: **Adam Smith, MD**
Clinic Name: **Artera Hospital**

ORDER
Order Date: **07/01/2025**
Specimen Receipt: **07/10/2025**
Test Run Date: **07/11/2025**
Artera ID: **AM-4Y-VRD-005K**
Accession Number: **ART-25-XXXXX**

CLINICAL AND PATHOLOGY
Clinical Tumor Stage: **T1c**
Pre-biopsy PSA: **3.8 ng/mL**
Gleason Score: **6 (3+3)**
Patient Age at Order Date: **70**
NCCN Risk: **Low**

PROGNOSTIC RISK OF DISEASE PROGRESSION

LOW

ArteraAI Prognostic Raw Score=0.13

10-YEAR RISK OF DISTANT METASTASIS
(With standard of care treatment)*

>35% HIGH
10% INTERMEDIATE
3% LOW
<1%
THIS PATIENT **1.4% RISK**

95% CI: 0.8%-2.1%

10-YEAR RISK OF PROSTATE CANCER SPECIFIC MORTALITY
(With standard of care treatment)*

0.6%
95% CI: 0.3%-1.1%

ACTIVE SURVEILLANCE (AS) INSIGHTS

THIS PATIENT

May Consider Active Surveillance
ArteraAI Low Risk (<3% 10-year DM)

May Consider Definitive Therapy
ArteraAI Int.-High Risk (>3% 10-year DM)

This patient's estimated 10-year risk of distant metastasis suggests that **active surveillance** per guideline recommendations may be an appropriate treatment option. Definitive therapy may still be an appropriate option for this patient.

In the validation cohort, no prostate cancer specific mortality events were observed in the ArteraAI Low Risk group within 10 years of diagnosis.

The ArteraAI Prostate Test results are provided to support risk-based decisions within the recommended guidelines, taking into consideration all other patient factors.

***These prognostic estimates reflect expected outcomes following standard treatment pathways, such as surveillance, surgery or radiation (including brachytherapy) and adjunctive androgen deprivation therapy, aligned with current NCCN guideline recommendations.**

Reviewed by Laboratory Director
Joshua B. Kish, MD

07/11/2025 12:00PM
Review Date and Time (EST)

[By signing this I am confirming adequate quality of the material received, image reviewed and presence of cancer, unless otherwise noted in this report.]

A **Prognostic Risk:** The ArteraAI prognostic risk group can explain how aggressive the patient's prostate cancer is. The 10-year risk of distant metastasis is reported as a continuous variable with low-, intermediate-, and high-risk categories.

B **Additional Prognostic Endpoints:** In addition to the 10-year risk of distant metastasis, 10-year risk of prostate cancer-specific mortality is also reported. This can help provide more information to support optimized decision-making.

C **Active Surveillance Insights:** For men with NCCN very low-, low-, and favorable intermediate-risk prostate cancer, the test provides a binary indication of distant metastasis risk in a modern, real world active surveillance-managed cohort, indicating if the patient's progression risk may warrant earlier treatment.

NCCN Low/Very Low Risk
Example Test Report

ARTERA

Name: **John Doe**
Date of Birth: **08/08/1954**

ArteraAI Prostate Test Report

SPECIMEN DETAILS

Date of Biopsy: **05/08/2022**
Procedure: **Biopsy**

Specimen Site: **Prostate**
Specimen ID: **22-00129**

Gross Description: **Received and reviewed**
[1] H&E slide(s) labeled [22-00128]

SUPPLEMENTAL INFORMATION

D

PROGNOSTIC RISK

Comparison of this patient to those in same NCCN risk group



This patient has an estimated 10-year risk of metastasis that is **lower than 60%** of patients in the same NCCN very low/low risk group.

This report was electronically signed by Dr. Joshua B. Kish on 07/07/2025 at 12:00PM.

© 2026, ARTERA Inc.

D **Comparison With National Comprehensive Cancer Network (NCCN) Risk Group:** There is variability among patients within NCCN risk groups. A visualization is provided to show how the risk of metastasis, based on the ArteraAI risk score, compares to other patients with NCCN low/very low-risk disease.